[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. DOI: 10.3322/caac.21834.
[2] Vibert E, Canedo L, Adam R. Strategies to treat primary unre‐sectable colorectal liver metastases[J]. Semin Oncol, 2005,32(6 Suppl 8):33-39. DOI: 10.1053/j.seminoncol.2005.07.015.
[3] O’Leary C, Soulen MC, Shamimi-Noori S. Interventional oncology approach to hepatic metastases[J]. Semin Intervent Radiol, 2020, 37(5):484-491. DOI: 10.1055/s-0040-1719189.
[4] Helmberger T. Interventional procedures for hepatic metastases [J]. Chirurg, 2010, 81(6):542-550. DOI: 10.1007/s00104-010-1888-4.
[5] Guenette JP, Dupuy DE. Radiofrequency ablation of colorectal hepatic metastases[J]. J Surg Oncol, 2010, 102(8): 978-987.DOI: 10.1002/jso.21658.
[6] Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neu‐roendocrine carcinomas:interventional treatment via transarte‐rial embolization, chemoembolization and thermal ablation[J].Eur J Radiol, 2009, 72(3):517-528. DOI: 10.1016/j.ejrad.2008.08.008.
[7] Fraker DL, Soulen M. Regional therapy of hepatic metastases [J]. Hematol Oncol Clin North Am, 2002, 16(4): 947-967.DOI: 10.1016/s0889-8588(02)00039-4.
[8] Lubner MG, Brace CL, Hinshaw JL, et al. Microwave tumor ablation:mechanism of action, clinical results, and devices[J]. J Vasc Interv Radiol, 2010, 21(8 Suppl):S192-203. DOI: 10.1016/j.jvir.2010.04.007.
[9] Laimer G, Johnston EW, Overduin CG, et al. International multisociety Delphi consensus for liver tumour thermal ablation:procedural and practice standards[J]. Lancet Oncol, 2026, 27(5):e259-e270. DOI: 10.1016/S1470-2045(26)00114-2.
[10] Shady W, Petre EN, Gonen M, et al. Percutaneous radiofre‐quency ablation of colorectal cancer liver metastases:factors af‐fecting outcomes--A 10-year experience at a single center[J]. Ra‐diology, 2016, 278(2):601-611. DOI: 10.1148/radiol.2015142489.
[11] van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metasta‐ses (COLLISION): an international, randomised, controlled,phase 3 non-inferiority trial[J]. Lancet Oncol, 2025, 26(2):187-199. DOI: 10.1016/S1470-2045(24)00660-0.
[12] Tinguely P, Ruiter SJS, Engstrand J, et al. A prospective multi‐centre trial on survival after Microwave Ablation VErsus Re‐section for Resectable Colorectal liver metastases (MAVER‐RIC)[J]. Eur J Cancer, 2023, 187: 65-76. DOI: 10.1016/j. ej‐ca.2023.03.038.
[13] Dijkstra M, van der Lei S, Puijk RS, et al. Efficacy of thermal ablation for small-size (0-3 cm) versus intermediate-size (3-5cm) colorectal liver metastases: results from the Amsterdam Colorectal Liver Met Registry (AmCORE)[J]. Cancers(Basel), 2023, 15(17):4346. DOI: 10.3390/cancers15174346.
[14] Sofocleous CT, Callstrom MR, Petre EN, et al. Real-time 3D confirmation of complete ablation with margins as a local cure for colorectal liver metastases: the ACCLAIM trial[J]. Trials,2025, 26(1):360. DOI: 10.1186/s13063-025-09006-2.
[15] Laimer G, Verdonschot KHM, Kopf L, et al. Multicenter and inter-software evaluation of ablative margins after thermal ablation of colorectal liver metastases[J]. Eur Radiol, 2025,35(2):1046-1056. DOI: 10.1007/s00330-024-10956-5.
[16] Paolucci I, Albuquerque Marques Silva J, Lin YM, et al. Iden‐tification of A0 minimum ablative margins for colorectal liver metastases: multicentre, retrospective study using deformable CT registration and artificial intelligence-based autosegmenta‐tion[J]. Br J Surg, 2024, 111(9): znae165. DOI: 10.1093/bjs/znae165.
[17] Ausania F, Borin A, Melendez R, et al. Microwave ablation of colorectal liver metastases: impact of a 10-mm safety margin on local recurrence in a tertiary care hospital[J]. Ann Hepatobi‐liary Pancreat Surg, 2021, 25(3):366-370. DOI: 10.14701/ahb‐ps.2021.25.3.366.
[18] Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases:ablation with clear margins (A0) provides the best local tumor control[J]. J Vasc Interv Radiol, 2018, 29(2):268-275.e1. DOI:10.1016/j.jvir.2017.08.021.
[19] Chlorogiannis DD, Sotirchos VS, Georgiades C, et al. The importance of optimal thermal ablation margins in colorectal liver metastases: a systematic review and meta-analysis of 21 studies[J]. Cancers (Basel), 2023, 15(24):5806. DOI: 10.3390/cancers15245806.
[20] Paolucci I, Overduin CG, Johnston EW, et al. International multisociety Delphi consensus for liver tumour thermal ablation:margin assessment[J]. Lancet Oncol, 2026, 27(5): e248-e258.DOI: 10.1016/S1470-2045(26)00143-9.
[21] van der Lei S, Kors N, Dijkstra M, et al. Exploring the upper limit:the added value of local treatment in patients with multi‐ple colorectal liver metastases:an Amsterdam Colorectal Liver Met Registry (AmCORE) -based study[J]. Cardiovasc Inter‐vent Radiol, 2026, 49(5):959-969. DOI: 10.1007/s00270-025-04260-y.
[22] Vogl TJ, Stefan H, Gruber-Rouh T, et al. The combination of transarterial chemoembolization and microwave ablation is superior to microwave ablation alone for liver metastases from colorectal cancer[J]. J Cancer Res Clin Oncol, 2024, 150(10):440. DOI: 10.1007/s00432-024-05951-8.
[23] Vogl TJ, Freichel J, Gruber-Rouh T, et al. Interventional treat‐ments of colorectal liver metastases using thermal ablation and transarterial chemoembolization: a single-center experience over 26 years[J]. Cancers (Basel), 2024, 16(9): 1756. DOI: 10.3390/cancers16091756.
[24] Zhu C, Liao JY, Liu YY, et al. Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies[J]. Mol Cancer,2024, 23(1):254. DOI: 10.1186/s12943-024-02171-z.
[25] Vijay J, Namboodiri N. Cryoablation for atrial fibrillation:biophysics and a contemporary step-by-step approach[J]. Indian Pacing Electrophysiol J, 2026, 26(1):5-12. DOI: 10.1016/j.ipej.2026.02.002.
[26] Xu JJ, Ni CX, Qin LD, et al. Cryoablation remodels the immune microenvironment in hepatocellular carcinoma: From mechanistic insights to clinical translation in combination immunotherapy[J]. World J Gastrointest Oncol, 2026, 18(6):118976. DOI: 10.4251/wjgo.v18.i6.118976.
[27] Khanmohammadi S, Behnoush AH, Akhlaghpoor S. Survival outcomes and quality of life after percutaneous cryoablation for liver metastasis:a systematic review and meta-analysis[J]. PLoS One, 2023, 18(8):e0289975. DOI: 10.1371/journal.pone.0289975.
[28] Gu S, Luo Q, Zhang Y, et al. Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarci‐noma:a phase 2 trial[J]. Nat Cancer, 2026, 7(1):60-79. DOI: 10.1038/s43018-025-01058-2.
[29] Zhang N, Li Z, Han X, et al. Irreversible electroporation: an emerging immunomodulatory therapy on solid tumors[J]. Front Immunol, 2022, 12:811726. DOI: 10.3389/fimmu.2021.811726.
[30] Narayanan G, Koethe Y, Gentile N. Irreversible electropora‐tion of the hepatobiliary system: current utilization and future av‐enues[J]. Medicina (Kaunas), 2024, 60(2):251. DOI: 10.3390/me‐dicina60020251.
[31] Spiers HVM, Lancellotti F, de Liguori Carino N, et al. Irre‐versible electroporation for liver metastases from colorectal cancer: a systematic review[J]. Cancers (Basel), 2023, 15(9):2428. DOI: 10.3390/cancers15092428.
[32] Meijerink MR, Ruarus AH, Vroomen LGPH, et al. Irreversible electroporation to treat unresectable colorectal liver metasta‐ses (COLDFIRE-2):a phase II, two-center, single-arm clinical trial[J]. Radiology, 2021, 299(2):470-480. DOI: 10.1148/radi‐ol.2021203089.
[33] O'Neill CH, Martin RCG. Cardiac synchronization and ar‐rhythmia during irreversible electroporation[J]. J Surg Oncol,2020, 122(3):407-411. DOI: 10.1002/jso.26041.
[34] Pallumeera M, Hong M, Giang JC, et al. Histotripsy: recent advances, clinical applications, and future prospects[J]. Cancers(Basel), 2025, 17(18):3072. DOI: 10.3390/cancers17183072.
[35] Song B, Queen H, Ferris SF, et al. Histotripsy-focused ultrasound treatment abrogates tumor hypoxia responses and stimulates antitumor immune responses in melanoma[J]. Mol Cancer Ther, 2025, 24(7):1088-1098. DOI: 10.1158/1535-7163.MCT-24-0715.
[36] Xu Z, Khokhlova TD, Cho CS, et al. Histotripsy:a method for mechanical tissue ablation with ultrasound[J]. Annu Rev Biomed Eng, 2024, 26(1):141-167. DOI: 10.1146/annurev-bioeng-073123-022334.
[37] Ziemlewicz TJ, Critchfield JJ, Mendiratta-Lala M, et al. The#HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors: one-year update of clinical outcomes[J]. Ann Surg, 2025, 282(6): 908-916. DOI:10.1097/SLA.0000000000006720.
[38] Liu BJ, Gao S, Guo JH, et al. Efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX or FOLFIRI plus drug-eluting bead transarterial chemoembolization in unresectable colorectal liver metastases[J]. J Clin Oncol,2026, 44(2_Suppl):53. DOI: 10.1200/JCO.2026.44.2_suppl.53.
[39] Schneider CCI, de Wit-van der Veen BJ, Jansen SMA, et al.High-dose transarterial radioembolization of hepatic metastases using yttrium-90 resin microspheres[J]. Cancers (Basel), 2025,17(24):3889. DOI: 10.3390/cancers17243889.
[40] Ou H, Li X, Chang S, et al. Advances in hepatic arterial perfu‐sion chemotherapy for hepatic metastases[J]. Front Oncol,2025, 15:1544061. DOI: 10.3389/fonc.2025.1544061.
[41] Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intrave‐nous therapy (FOLFIRI) for hepatic metastases from colorec‐tal cancer: final results of a phase Ⅲ study[J]. Anticancer Res,2012, 32(4):1387-1395.
[42] Arnold D, Pereira PL, Iezzi R, et al. Transarterial chemoem‐bolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases:effectiveness results from the CIREL study[J]. ESMO Open,2025, 10(3):104292. DOI: 10.1016/j.esmoop.2025.104292.
[43] Kuemmerli C, Hess V, Dutkowski P, et al. Hepatic artery infu‐sion chemotherapy for primary and secondary malignancies of the liver: state of the art and current high-level evidence[J].Pharmacology, 2024, 109(2):86-97. DOI: 10.1159/000537887.
[44] Mulcahy M , Salem R , Mahvash A ,et al. LBA21 Radioembo‐lization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase Ⅲ trial (EPOCH study)[J]. Ann Oncol, 2021, 32(Supplement 5):S1295. DOI: 10.1016/j.annonc.2021.08.2095.
[45] 中国医师协会外科医师分会,中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠外科学组,等. 结直肠癌肝转移诊断和综合治疗指南(2025版)[J]. 中华消化外科杂志,2025,24(8):943-968. DOI:10.3760/cma.j.cn115610-20250713-00468.
[46] Gupta S. Intra-arterial liver-directed therapies for neuroendo‐crine hepatic metastases[J]. Semin Intervent Radiol, 2013,30(1):28-38. DOI: 10.1055/s-0033-1333651.
[47] Soulen MC WE, Dey C. Randomized embolization trial for neuroendocrine tumors (RETNET)[C]//18th Annual Multidis‐ciplinary NET Medical Symposium, North American Neuroen‐docrine Tumor Society (NANETS 2025). AbstractsEndocrine,2025, 116: C12. DOI: 10.1530/endoabs.116.C12.
[48] Li R, Li X, You X, et al. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: study protocol for a prospective, randomized, controlled trial[J].Cancer Med, 2024, 13(8):e7131. DOI: 10.1002/cam4.7131.
[49] 中国抗癌协会神经内分泌肿瘤专业委员会, 陈洁, 聂勇战,等 . 中国抗癌协会神经内分泌肿瘤诊治指南(2025 年版)[J].中国癌症杂志, 2025, 35(1):85-142. DOI: 10.19401/j.cnki.1007-3639.2025.01.010.
[50] Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021,19(7):839-868. DOI: 10.6004/jnccn.2021.0032.